



Federica Lo Prinzi

Current Position

Consultant Medical Oncologist

Azienda Ospedaliera Umberto I di Siracusa – Syracuse, Italy | February 2026 – Present

Professional Experience / Training

External Training Network in Medical Oncology

University Hospital Policlinico G. Rodolico - San Marco, Catania | April 2025 – January 2026

- Clinical activity in Day Hospital and oncology follow-up outpatient clinic

Hepatobiliary Tumor Research Unit – San Raffaele Hospital, Milan | April 2024 – March 2025

- Database development and management (Excel)
- Statistical data analysis and drafting of scientific articles
- Clinical activity in Day Hospital and oncology outpatient clinic

Training Network in Medical Oncology – San Giovanni Addolorata Hospital, Rome | January 2023 – January 2024

- Management of chemotherapy, immunotherapy, and TKIs for gastrointestinal and brain malignancies
 - Outpatient oncology follow-up
-

Education and Training

- **Residency in Medical Oncology**, Fondazione Policlinico Campus Bio-Medico, Rome | January 2021 – January 2026
 - **ICH Good Clinical Practice E6 Certification** | 15 May 2025
 - **ESMO Advanced Course on Cholangiocarcinoma (travel grant)** | Madrid, 25–26 October 2024
 - **Medical License** | March 2020, registered at the Medical Council of Catania
 - **MD Degree in Medicine and Surgery (110/110 cum laude)** | University of Catania, 18 July 2019
-

Languages

- Italian: Native
 - English: B2 (Upper-intermediate)
-

Awards and Conference Presentations

- **22-24 January 2026** - *Outcomes of cisplatin, gemcitabine, and durvalumab according to TOPAZ-1 study eligibility: a large global analysis in a real-world setting* -EASL Liver Cancer Summit 2026 (First Author, Travel Grant)
- **2–5 July 2025** – *Negative impact of corticosteroid use on outcomes in patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab: a large real-world global population*, ESMO Gastrointestinal Cancers Congress, Barcelona (First Author, Travel Grant)
- **2–5 July 2025** – *Comparative effectiveness of Atezolizumab plus Bevacizumab versus Tremelimumab plus Durvalumab in a real-world setting*, ESMO Gastrointestinal Cancers Congress, Barcelona (First Author, Travel Grant)
- **29–31 May 2025** – *Clinical characteristics and outcomes of patients with fibrolamellar hepatocellular carcinoma: analysis of a large population using real-world data*, THE LIVER WEEK 2025, South Korea (First Author, Travel Grant)
- **9–11 April 2025** – *Negative impact of steroid use on outcomes in patients with advanced BTC treated with cisplatin, gemcitabine and durvalumab*, Cholangiocarcinoma Foundation Annual Conference, Salt Lake City, Utah (First Author, Accepted Abstract)
- **3–5 March 2025** – *Impact of molecular alterations in patients with advanced cholangiocarcinoma (BTC) treated with cisplatin, gemcitabine and durvalumab (CGD): a large global study*, ESMO TAT Congress, Paris (First Author, Travel Grant)
- **26–29 June 2024** – *The impact of Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer (LARC): a real-world Italian multicenter experience*, ESMO Gastrointestinal Cancers Congress, Munich, Germany (First Author, Accepted Abstract)
- **9–10 November 2024** – *The impact of Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer (LARC): a real-world Italian multicenter experience*, AIOM Congress, Rome (First Author, Accepted Abstract)
- **2–5 July 2025** – *Real-world outcomes of second-line chemotherapy in biliary tract cancer following chemo-immunotherapy: insights from a single Italian institute*, ESMO Gastrointestinal Cancers Congress, Barcelona (Co-author)

- **3–5 March 2025** – *Prognostic impact of target-directed therapies in biliary tract cancer patients harboring molecular alterations*, ESMO TAT Congress, Paris (Co-author)
 - **June 2023** – *Aflibercept-based and bevacizumab-based second-line regimens in RAS/BRAF wild type metastatic colorectal cancer: Propensity score weighted-analysis from a multicenter cohort*, ESMO GI Congress, Barcelona (Co-author)
 - **June 2023** – *Aflibercept-based and bevacizumab-based second-line regimens in RAS mutant metastatic colorectal cancer: Propensity score weighted-analysis from a multicenter cohort*, ESMO GI Congress, Barcelona (Co-author)
-

Memberships and Editorial Activity

Memberships:

- European Society of Medical Oncology (ESMO)
- Italian Association of Medical Oncology (AIOM)

Ad hoc Reviewer for:

- Discover Oncology
- Scientific Reports
- European Journal of Medical Research

Publications

Camera S, Fornaro L, Rimini M, Persano M, Rizzato MD, Saborowski A, Antonuzzo L, Rossari F, Satake T, Peeters F, Salani F, Bozzarelli S, Corallo S, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Gallio C, Tamberi S, Finkelmeier F, Giordano G, Chiara P, Chon HJ, Braconi C, Qaisar A, Pastorino A, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Couto N, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquez MG, Leo S, Melo Alvim C, Roque R, Farinea G, Genovesi V, De Rosa A, Lavacchi D, **Lo Prinzi F**, Passeri L, Ferrara M, Foti S, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Tesini G, Esposito L, Casadio C, Himmelsbach V, Landriscina M, Ahcene Djaballah S, Bekaii-Saab T, Masi G, Vogel A, Lonardi S, Vivaldi C, Rimassa L, Casadei-Gardini A. (2026) Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab. *Target Oncology*.

Lo Prinzi, F., Rossari, F., De Rosa, A., Vivaldi, C., Kudo, M., Shimose, S., Suda, G., Camera, S., Foti, S., Rizzato, M. D., Salani, F., Nishida, N., Shirono, T., Sakamoto, N., Passeri, L., Ferrara, M.,

Soldà, C., Cesario, S., Ueshima, K., Niizeki, T., Sho, T., Persano, M., Vitiello, F., Invernizzi, F., Lonardi, S., Masi, G., Rimini, M., & Casadei Gardini, A. (2025). Efficacy and safety of lenvatinib versus sorafenib in recurrent HCC after liver transplant: A multi-center real-world study. *Hepatology Research*.

Pirrone, C., Malapelle, U., Pepe, F., **Lo Prinzi, F.**, Nichetti, F., Saborowski, A., Antonuzzo, L., Camera, S., Satake, T., Peeters, F., Vivaldi, C., Pressiani, T., Lucchetti, J., Kim, J. W., Abidoye, O., Rapposelli, I. G., Tamberi, S., Finkelmeier, F., Giordano, G., ... Casadei-Gardini, A. (2025). Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab. *European Journal of Cancer*.

Rimini, M., Presi, S., Mohammadi, K., Pipitone, G. B., Raucci, A. R., Ratti, F., Pedica, F., Foti, S., Camera, S., Ferrara, M., Passeri, L., Vanella, G., Rossari, F., **Lo Prinzi, F.**, Persano, M., Vitiello, F., Cangì, M. G., Pecciarini, L., Arcidiacono, P. G., ... Casadei-Gardini, A. (2025). Comprehensive genetic analysis in biliary tract cancer: A prospective single-center experience. *ESMO Gastrointestinal Oncology*, 9, 100227.

Vitiello, F., Vivaldi, C., Rizzato, M. D., Saborowski, A., Antonuzzo, L., Rossari, F., Salani, F., Kim, J. W., Rapposelli, I. G., Tamburini, E., Rimini, M., **Lo Prinzi, F.**, Satake, T., Peeters, F., Pressiani, T., Lucchetti, J., Abidoye, O., Gallio, C., Tamberi, S., ... Bekaii-Saab, T. (2025). Impact of antibiotic therapy in patients with cholangiocarcinoma treated with chemoimmunotherapy. *Oncology*, 1–26.

Persano, M., Rimini, M., Salani, **F.**, **Lo Prinzi, F.**, Nichetti, F., Saborowski, A., Antonuzzo, L., Passeri, L., Satake, T., Peeters, F., Vivaldi, C., Pressiani, T., Lucchetti, J., Kim, J. W., Abidoye, O., Corallo, S., Rapposelli, I. G., Tamberi, S., Finkelmeier, F., ... Casadei-Gardini, A. (2025). A prognostic index for advanced biliary tract cancer treated with cisplatin, gemcitabine and durvalumab: The MAGIC-D index. *Liver International*, 45(7), e70181.

Lo Prinzi, F., Salani, F., Camera, S., Rizzato, M. D., Saborowski, A., Antonuzzo, L., Rossari, F., Satake, T., Peeters, F., Pressiani, T., Lucchetti, J., Kim, J. W., Abidoye, O., Rapposelli, I. G., Gallio, C., Tamberi, S., Finkelmeier, F., Giordano, G., ... Casadei-Gardini, A. (2025). Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide population. *International Journal of Cancer*. Advance online publication.

Lo Prinzi, F., Rossari, F., Silletta, M., Camera, S., Foti, S., Persano, M., Vitiello, F., Di Giacomo, E., Polito, M. G., Rimini, M., & Casadei-Gardini, A. (2025). Comparative effectiveness of atezolizumab plus bevacizumab versus tremelimumab plus durvalumab in patients with hepatocellular carcinoma (HCC) in a real-world setting. *Targeted Oncology*, 20(4), 707–713.

Rossari, F., Lavacchi, D., Alimenti, E., Soldà, C., Salani, F., Esposito, L., Foti, S., Camera, S., Persano, M., **Lo Prinzi, F.**, Vitiello, F., Pellegrini, E., Bruccoleri, M., Rizzato, M. D., Caccese, M., Rapposelli, I. G., Guidolin, A., De Rosa, A., Antonuzzo, L., ... Casadei-Gardini, A. (2025). Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment. *ESMO Gastrointestinal Oncology*, 8, 100186.

Rimini, M., Fornaro, L., **Lo Prinzi, F.**, Rizzato, M. D., Saborowski, A., Antonuzzo, L., Rossari, F., Vivaldi, C., Satake, T., Peeters, F., Pressiani, T., Lucchetti, J., Kim, J. W., Abidoye, O., Rapposelli, I. G., Tamberi, S., Finkelmeier, F., Giordano, G., Pircher, C., ... Casadei-Gardini, A. (2025). Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study. *International Journal of Cancer*. Advance online publication.

Lucchetti, J., Di Giacomo, E., Polito, M. G., Nitti, D., **Lo Prinzi, F.**, Barnini, G., Galbato Muscio, L., Pezzola, G., Di Lascio, C., Vincenzi, B., & Tonini, G. (2024). Clinical experience of complete pathological response in MSI-H and PD-L1 positive inoperable gastric cancer treated with ICIs and chemotherapy: Two case reports. *Gavin Publishers*.

Camera, S., Rossari, F., Foti, S., Vitiello, F., Persano, M., **Lo Prinzi, F.**, De Cobelli, F., Aldrighetti, L., Cascinu, S., Rimini, M., & Casadei-Gardini, A. (2025). HER2 pathway in biliary tract cancer: A snapshot of the current understanding and future directions. *Targeted Oncology*, 20(2), 269–280.

Rimini, M., Foti, S., Camera, S., Rossari, F., Vitiello, F., **Lo Prinzi, F.**, Aldrighetti, L., De Cobelli, F., Pedica, F., Arcidiacono, P. G., Persano, M., Cascinu, S., & Casadei-Gardini, A. (2024). Survival outcomes of durvalumab in combination with cisplatin and gemcitabine in advanced biliary tract cancer: Real world results from a single Italian institution. *Oncology*.

Lo Prinzi, F., Rossari, F., Silletta, M., Foti, S., Camera, S., Vitiello, F., Amadeo, E., De Cobelli, F., Aldrighetti, L., Rimini, M., & Casadei-Gardini, A. (2024). Intermediate hepatocellular carcinoma: New horizons and prospects for our patients. *Expert Review of Gastroenterology & Hepatology*.

Lo Prinzi, F., Salani, F., Rimini, M., Rizzato, M. D., Antonuzzo, L., Camera, S., Satake, T., Vandeputte, H., Vivaldi, C., Pressiani, T., Lucchetti, J., Kim, J. W., Abidoye, O., Rapposelli, I. G., Tamberi, S., Finkelmeier, F., Giordano, G., Pircher, C., Chon, H. J., ... Casadei-Gardini, A. (2024). Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: A large real-life worldwide population. *The Oncologist*.

Amadeo, E., Foti, S., Camera, S., Rossari, F., Persano, M., **Lo Prinzi, F.**, Vitiello, F., Casadei-Gardini, A., & Rimini, M. (2024). Developing targeted therapeutics for hepatocellular carcinoma: A critical assessment of promising phase II agents. *Expert Opinion on Investigational Drugs*.

Fulgenzi, C. A. M., Scheiner, B., D'Alessio, A., Mehan, A., Manfredi, G. F., Celsa, C., Nishida, N., Ang, C., Marron, T. U., Wu, L., Saeed, A., Wietharn, B., Cammarota, A., Pressiani, T., Pinter, M., Sharma, R., Cheon, J., Huang, Y.-H., Lee, P.-C., **Lo Prinzi, F.** ... Pinato, D. J. (202?). Immunotherapy vs best supportive care for patients with hepatocellular cancer with Child-Pugh B dysfunction. *Cancer*.

Lucchetti, J., Angotti, L., Parisi, A., Basso, M., Polito, M. G., Zoratto, F., Di Giacomo, E., Nitti, D., Minelli, A., Salvatore, L., Calegari, M. A., **Lo Prinzi, F.**, Gemma, D., Signorelli, C., Veroli, M., Anghelone, A., Galbato Muscio, L., Di Cocco, B., Trombetta, G., ... Tonini, G. (2025). Aflibercept-based and bevacizumab-based second line regimens in patients with metastatic colorectal cancer: Propensity score weighted-analysis from a multicenter cohort. *Clinical Colorectal Cancer*. Advance online publication.

Gallo, P., Silletta, M., **Lo Prinzi, F.**, Farolfi, T., & Coppola, A. (2023). Hepatocellular carcinoma and non-alcoholic fatty liver disease: A modern context for an ancient disease. *Journal of Clinical Medicine*.

Formica, V., Morelli, C., Conca, V., Calegari, M. A., Lucchetti, J., Dell'Aquila, E., Schirripa, M., Messina, M., Salvatore, L., **Lo Prinzi, F.**, Dima, G., Trovato, G., Riondino, S., Roselli, M., Skoulidis, F., Arkenau, H.-T., & Cremolini, C. (2023). Irinotecan- vs. oxaliplatin-based doublets in KRASGC-mutated metastatic colorectal cancer—A multicentre propensity-score-matched retrospective analysis. *Cancers*.

Gallo, P., Silletta, M., De Vincentis, A., **Lo Prinzi, F.**, Terracciani, F., Di Fazio, G., Flagiello, V., Vespasiani Gentilucci, U., Antonelli Incalzi, R., & Picardi, A. (2022). Sarcopenia in hepatocellular carcinoma: Pathogenesis and management. *Chemotherapy*.